中国医药科学
中國醫藥科學
중국의약과학
China Medicine and Pharmacy
2015年
14期
186-188
,共3页
慢性阻塞性肺病%高选择性β1受体阻滞剂%肺功能
慢性阻塞性肺病%高選擇性β1受體阻滯劑%肺功能
만성조새성폐병%고선택성β1수체조체제%폐공능
Chronic obstructive pulmonary disease%Highly selective β-blocker%Pulmonary function
目的 探讨高选择性β1受体阻滞剂对于慢性阻塞性肺疾病患者肺功能的影响. 方法 2012年2月~2013年12月期间,在我院门诊及住院部收集慢性阻塞性肺疾病(COPD)病例60例,随机分入两组,其中对照组(30例)采用"吸入性糖皮质激素(ICS)+β2兴奋剂"治疗,而治疗组(30例)在此基础上再联合高选择性β1受体阻滞剂治疗,比较其对患者肺功能的影响. 结果 治疗后,治疗组SGRQ评分的症状部分、活动部分、影响部分及总分,均明显低于对照组,差异有统计学意义(P<0.05);并且,在LVEF、FEV1、FEV1/FVC方面,治疗后治疗组改善率也明显优于对照组,差异有统计学意义(P<0.05).结论 高选择性β1受体阻滞剂对于COPD患者肺功能有着积极影响,并且安全可靠,值得临床进一步推广应用.
目的 探討高選擇性β1受體阻滯劑對于慢性阻塞性肺疾病患者肺功能的影響. 方法 2012年2月~2013年12月期間,在我院門診及住院部收集慢性阻塞性肺疾病(COPD)病例60例,隨機分入兩組,其中對照組(30例)採用"吸入性糖皮質激素(ICS)+β2興奮劑"治療,而治療組(30例)在此基礎上再聯閤高選擇性β1受體阻滯劑治療,比較其對患者肺功能的影響. 結果 治療後,治療組SGRQ評分的癥狀部分、活動部分、影響部分及總分,均明顯低于對照組,差異有統計學意義(P<0.05);併且,在LVEF、FEV1、FEV1/FVC方麵,治療後治療組改善率也明顯優于對照組,差異有統計學意義(P<0.05).結論 高選擇性β1受體阻滯劑對于COPD患者肺功能有著積極影響,併且安全可靠,值得臨床進一步推廣應用.
목적 탐토고선택성β1수체조체제대우만성조새성폐질병환자폐공능적영향. 방법 2012년2월~2013년12월기간,재아원문진급주원부수집만성조새성폐질병(COPD)병례60례,수궤분입량조,기중대조조(30례)채용"흡입성당피질격소(ICS)+β2흥강제"치료,이치료조(30례)재차기출상재연합고선택성β1수체조체제치료,비교기대환자폐공능적영향. 결과 치료후,치료조SGRQ평분적증상부분、활동부분、영향부분급총분,균명현저우대조조,차이유통계학의의(P<0.05);병차,재LVEF、FEV1、FEV1/FVC방면,치료후치료조개선솔야명현우우대조조,차이유통계학의의(P<0.05).결론 고선택성β1수체조체제대우COPD환자폐공능유착적겁영향,병차안전가고,치득림상진일보추엄응용.
Objective To explore the influence of highly selective β-blocker on pulmonary function of patients with chronic obstructive pulmonary disease.Methods 60 patients with chronic obstructive pulmonary disease(COPD) who were admitted to clinic and inpatient department in our hospital from February, 2012 to December, 2013 were randomly allocated to the control group and the treatment group, with 30 in each. Patients in the control group were received "inhaled corticosteroids (ICS) + beta 2 doping" treatment while patients in the treatment group were received this treatment combined with highly selective β-blocker. Its influences on pulmonary function of patients were compared.ResultsAfter treatment, scores of symptoms, activity, influence and total score in SGRQ scoring of the treatment group were all significantly lower than that of the control group. The differences were statistically significant(P<0.05). In addition, improvement rates in LVEF, FEV1, FEV1/FVC aspects of the treatment group aftr treatment were all significantly superior to those of the control group. The difference was statistically significant (P<0.05).Conclusion High selectiveβ-blocker has a positive effect on pulmonary function of patients with COPD and it is safe and reliable which is worthy of further promotion and application in clinic.
